Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 13Myeloid 13Lymphoid 11Classical hematology 4Plasma cell 3Dermatologic 1

Conditions

Multiple Myeloma 4Myelodysplastic Syndromes 3Lymphoma 3Leukemia 3Hematologic Neoplasms 2Neoplasms, Plasma Cell 1Hodgkin Disease 1Hematologic Diseases 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 89fludarabine phosphate 77Mycophenolic Acid 53Tacrolimus 52Peripheral Blood Stem Cell Transplantation 50Busulfan 44Whole-Body Irradiation 43Antilymphocyte Serum 41fludarabine 37Cyclosporine 36Filgrastim 32Melphalan 27Methotrexate 26Radiotherapy 23Cord Blood Stem Cell Transplantation 19Methylprednisolone 18Granulocyte Colony-Stimulating Factor 16Sirolimus 14Etoposide 13Alemtuzumab 12thymoglobulin 11sargramostim 11Stem Cell Transplantation 11Rituximab 11Thiotepa 9Azacitidine 8Cytarabine 7Psychiatric Rehabilitation 6Prednisone 6Flow Cytometry 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × AP 1903 reagent × Plasma cell × Clear all
NCT02477878 2022-07-12

Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant

Bellicum Pharmaceuticals

Phase 1 Active not recruiting
10 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT02786485 2020-10-05

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

Bellicum Pharmaceuticals

Phase 1 Withdrawn
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Hematologic Neoplasms

NCT01875237 2019-07-16

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡